Profile
Sector:
HealthcareIndustry:
Diagnostics & ResearchCountry:
Hong KongIPO:
16 July 2021Website:
http://www.prenetics.comNext earnings report:
20 November 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Mon, 04 Nov 2024 14:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
PRE Latest News
CHARLOTTE, N.C., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Prenetics, (NASDAQ: PRE) a leading health sciences company, announced today that management will participate in the Sidoti Virtual Micro Cap Conference being held on November 13-14, 2024.
ATLANTA , June 5, 2024 /PRNewswire/ -- DYMO®, a leading provider of innovative labeling solutions and part of the Newell Brands global portfolio, and Taylor , a renowned name in custom label manufacturing, have announced a strategic partnership that makes custom-printed LabelWriter® labels available for use with DYMO LabelWriter® 5 Series printers. "We are excited to join forces with Taylor to offer our consumers unparalleled custom labeling solutions for the DYMO LabelWriter 5 Series, saving them time, money and effort," said Liesbet De Soomer, DYMO's Global Marketing Director.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Prenetics Global Limited (PRE) closed the most recent trading day at $0.89, making no change from the previous trading session.
Prenetics Global Limited (PRE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
What type of business is Prenetics Global Limited?
Prenetics Global Limited, a health sciences company, focuses on advancing consumer and clinical health. The company's consumer initiatives is led by IM8, a new health and wellness brand. Its prevention arm, CircleDNA, uses next-generation sequencing (NGS) technology to offer comprehensive consumer DNA test. It also develops and commercializes multi-cancer early detection technologies. In addition, the company offers a range of genomic profiling panels tailored for requirements and clinician needs, including ACTOnco, ACT HRD, ACTFusion, and ACTDrug tests. Further, the company offers ACTLiquid Pro, a sequencing based liquid biopsy assay for pan-solid tumors; ACTMonitor, which provides real time monitoring of drug resistance, treatment response, and cancer recurrence; and ACT Risk, which manages the cancer risk. Additionally, it is involved in the sports distribution activities providing sports nutrition products to fitness facilities. The company operates in Taiwan, Hong Kong, the United Kingdom, and internationally. The company was founded in 2014 and is based in Quarry Bay, Hong Kong and has a presence in the United States.
What sector is Prenetics Global Limited in?
Prenetics Global Limited is in the Healthcare sector
What industry is Prenetics Global Limited in?
Prenetics Global Limited is in the Diagnostics & Research industry
What country is Prenetics Global Limited from?
Prenetics Global Limited is headquartered in Hong Kong
When did Prenetics Global Limited go public?
Prenetics Global Limited initial public offering (IPO) was on 16 July 2021
What is Prenetics Global Limited website?
https://www.prenetics.com
Is Prenetics Global Limited in the S&P 500?
No, Prenetics Global Limited is not included in the S&P 500 index
Is Prenetics Global Limited in the NASDAQ 100?
No, Prenetics Global Limited is not included in the NASDAQ 100 index
Is Prenetics Global Limited in the Dow Jones?
No, Prenetics Global Limited is not included in the Dow Jones index
When was Prenetics Global Limited the previous earnings report?
No data
When does Prenetics Global Limited earnings report?
The next expected earnings date for Prenetics Global Limited is 20 November 2024